ZMYND11

Across TCGA pan-cancer cohorts, ZMYND11 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZMYND11 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZMYND11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZMYND11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where ZMYND11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.878	0.651	.001	46	view →
CCRCC	DFS	Quartile	III,IV	0.798	0.233	.002	31	view →
UCEC	DFS	Median	All	0.841	0.964	.018	10	view →
LUAD	DFS	Tertile	III,IV	0.547	0.879	.020	8	view →
LSCC	OS	Median	III,IV	0.409	0.882	.004	8	view →
HNSC	DFS	Tertile	IV	0.568	0.857	.018	6	view →
GBM	OS	Median	All	0.449	0.306	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZMYND11–PDAC (DFS)

Open the PDAC breakdown →